Literature DB >> 30541725

Predictive Role of Ki-67 and Proliferative-Cell Nuclear Antigen (PCNA) in Recurrent Cholesteatoma.

Ela Araz Server1, Çiğdem Kalaycık Ertugay1, Sevim Baykal Koca2, Ecem Sevim Longur1, Özgür Yiğit1, Hasan Demirhan1, Yasemin Çakır2.   

Abstract

OBJECTIVES: To investigate the potential use of Ki-67 and pronuclear cell antigen (PCNA) as indicators of recurrent cholesteatoma.
MATERIAL AND METHODS: Patients who had been diagnosed with cholesteatoma and who had undergone canal wall-down mastoidectomy were included in this study. Subjects were divided into two groups: recurrent and non-recurrent (i.e., cases without recurrence for at least 2 years). Ossicular pathologies were recorded. Histopathologic specimens were stained for Ki-67 and PCNA and the percentages of stained cells were calculated.
RESULTS: Neither group demonstrated a significant difference in terms of total Ki-67 per cell, Ki-67-stained cell counts, Ki-67-staining percentages, total PCNA per cell, PCNA-stained cell counts, or PCNA-staining percentages (p>0.05). No significant relationship was noted between the staining percentages for either Ki-67 or PCNA and the incudostapedial involvement (p>0.05); however, a significant relationship was noted between Ki-67 staining and malleus involvement (p<0.05).
CONCLUSION: Although the recurrent and non-recurrent cholesteatoma groups showed no significant differences in terms of the percentages of stained cells for either Ki-67 or PCNA, we detected high Ki-67 staining in the malleus involvement group. We concluded that cell-proliferation markers could not be defined as indicators of recurrence of cholesteatoma, but they could be defined as indicators of destructive patterns of this disease.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30541725      PMCID: PMC6483425          DOI: 10.5152/iao.2018.4976

Source DB:  PubMed          Journal:  J Int Adv Otol        ISSN: 1308-7649            Impact factor:   1.017


  19 in total

1.  Identification of Id1 in acquired middle ear cholesteatoma.

Authors:  Quan-An Zhang; Yuki Hamajima; Qing Zhang; Jizhen Lin
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-03

Review 2.  The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma.

Authors:  Shumin Xie; Xiaoli Wang; Jihao Ren; Wei Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-16       Impact factor: 2.503

Review 3.  Proliferating cell nuclear antigen (PCNA): ringmaster of the genome.

Authors:  T Paunesku; S Mittal; M Protić; J Oryhon; S V Korolev; A Joachimiak; G E Woloschak
Journal:  Int J Radiat Biol       Date:  2001-10       Impact factor: 2.694

Review 4.  Acquired cholesteatoma epithelial hyperproliferation: Roles of cell proliferation signal pathways.

Authors:  Shumin Xie; Yuyan Xiang; Xiaoli Wang; Hongmiao Ren; Tuanfang Yin; Jihao Ren; Wei Liu
Journal:  Laryngoscope       Date:  2016-03-15       Impact factor: 3.325

5.  Detection of macrophage migration inhibitory factor (MIF) in human cholesteatomas and functional implications of correlations to recurrence status and to expression of matrix metalloproteinases-3/9, retinoic acid receptor-beta, and anti-apoptotic galectin-3.

Authors:  G Choufani; R Ghanooni; C Decaestecker; K Delbrouck; P Simon; M P Schüring; Y Zick; S Hassid; H J Gabius; R Kiss
Journal:  Laryngoscope       Date:  2001-09       Impact factor: 3.325

6.  Determination of the levels of expression of sarcolectin and calcyclin and of the percentages of apoptotic but not proliferating cells to enable distinction between recurrent and nonrecurrent cholesteatomas.

Authors:  G Choufani; V Mahillon; C Decaestecker; T Lequeux; A Danguy; I Salmon; H J Gabius; S Hassid; R Kiss
Journal:  Laryngoscope       Date:  1999-11       Impact factor: 3.325

7.  Some markers of proliferative activity in cholesteatoma epithelium in adults.

Authors:  Ewa Olszewska; Stanisław Chodynicki; Lech Chyczewski; Marek Rogowski
Journal:  Med Sci Monit       Date:  2006-07-12

Review 8.  The disease recurrence rate after the canal wall up or canal wall down technique in adults.

Authors:  Kelly G P Kerckhoffs; Maarten B J Kommer; Thom H L van Strien; Simeon J A Visscher; Hanneke Bruijnzeel; Adriana L Smit; Wilko Grolman
Journal:  Laryngoscope       Date:  2015-09-25       Impact factor: 3.325

9.  Aggressiveness and quantification of epithelial proliferation of middle ear cholesteatoma by MIB1.

Authors:  Y Mallet; J Nouwen; M Lecomte-Houcke; A Desaulty
Journal:  Laryngoscope       Date:  2003-02       Impact factor: 3.325

10.  Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity.

Authors:  Mahmood A Hamed; Seiichi Nakata; Kazuya Shiogama; Kenji Suzuki; Ramadan H Sayed; Yoichi Nishimura; Noboru Iwata; Kouhei Sakurai; Badawy S Badawy; Ken-Ichi Inada; Hayato Tsuge; Yutaka Tsutsumi
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-12       Impact factor: 3.372

View more
  2 in total

Review 1.  Endotyping of Cholesteatoma: Which Molecular Biomarkers? A Systematic Review.

Authors:  Elena Cantone; Claudio Di Nola; Eugenio De Corso; Michele Cavaliere; Giusi Grimaldi; Anna Rita Fetoni; Gaetano Motta
Journal:  J Pers Med       Date:  2022-08-21

2.  Differential Expression of Ki-67 and P27 in Cholesteatoma Compared to Skin Tissue Predicts the Prognosis of Adult Acquired Cholesteatoma.

Authors:  Serkan Türkili; Kemal Görür; Onur İsmi; Ebru Serinsöz Linke; Yusuf Vayısoğlu; Cengiz Özcan
Journal:  J Int Adv Otol       Date:  2021-07       Impact factor: 1.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.